Deliver Your News to the World

Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe


WEBWIRE

Berlin.– Bayer Schering Pharma’s new low-dose oral contraceptive YAZ® has been approved in the EU.YAZ® will be the first oral contraceptive on the European market containing the unique progestin drospirenone combined with a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone tablets and four days of placebo.

YAZ® will be launched in all major European markets in autumn 2008. In the U.S. YAZ® has been available since 2006 where it is the only oral contraceptive ever approved for three distinct indications: contraception, treatment of moderate acne as well as treatment of the emotional and physical symptoms associated with PMDD (Premenstrual Dysphoric Disorder), such as mood swings, irritability, anxiety, food cravings, breast tenderness, bloating, and headache. Bayer Schering Pharma also plans to submit the YAZ® Acne and PMDD indication for registration in Europe.

“We are absolutely thrilled with the pan-European approval of YAZ®, the latest member of our blockbuster drospirenone-based product family” said Philip Smits, M.D., Head of Bayer Schering Pharma’s Business Unit Women’s Healthcare. “YAZ® offers women an innovative method of contraception with additional benefits, which other oral contraceptives do not have. YAZ®, with its 24-day regimen and the mode of action of its progestin drospirenone, offers one-of-a-kind benefits to women.”



WebWireID65076





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.